Water

Water

SCHEMBL5637133

O.Sc1nnc(-c2cccs2)[nH]1

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO

The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 known ✓ O00255 4/20 0.41
ADORA3 known ✓ P0DMS8 1/20 0.39
ADORA2A known ✓ P29274 1/20 0.39
ADORA2B known ✓ P29275 1/20 0.39
ADORA1 known ✓ P30542 1/20 0.39
KDM4E B2RXH2 8/20 0.45
HPGD P15428 7/20 0.45
ALDH1A1 P00352 7/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
HSD17B10 Q99714 2/20 0.45
MAPT P10636 5/20 0.41
KMT2A Q03164 4/20 0.41
GAA P10253 4/20 0.41
GLA P06280 2/20 0.41
LMNA P02545 2/20 0.41
HTT P42858 2/20 0.41
MAPK1 P28482 1/20 0.41
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8626463 0.98 KDM4E (0.46) KDM4EHPGDALDH1A1SMN1; SMN2NPC1
SCHEMBL417270 0.76 GAA (0.49) KDM4EHPGDALDH1A1SMN1; SMN2NPC1
SCHEMBL22977618 0.76 KDM4E (0.47) KDM4EHPGDALDH1A1SMN1; SMN2NPC1
SCHEMBL29290126 0.74 KDM4E (0.57) KDM4EHPGDALDH1A1SMN1; SMN2NPC1
SCHEMBL6410721 0.68 BCAT1 (0.40) KDM4EHPGDALDH1A1SMN1; SMN2NPC1
SCHEMBL6403484 0.66 ADORA3 (0.41) KDM4EHPGDALDH1A1SMN1; SMN2NPC1
SCHEMBL11051662 0.66 MAPT (0.55) KDM4EHPGDALDH1A1SMN1; SMN2NPC1
SCHEMBL8629006 0.65 KDM4E (0.43) KDM4EHPGDALDH1A1SMN1; SMN2NPC1
SCHEMBL1849836 0.65 POLB (0.44) KDM4EHPGDALDH1A1SMN1; SMN2NPC1
SCHEMBL4328366 0.65 KDM4E (0.43) KDM4EHPGDALDH1A1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006103345-A1 TYROSINASE INHIBITORS AND THEIR USE FOR TREATING HYPERPIGMENTARY DISORDERS GALDERMA RESEARCH & DEVELOPMENT (FR) 2006-10-05 WO claimed
WO-2006103345-A1 TYROSINASE INHIBITORS AND THEIR USE FOR TREATING HYPERPIGMENTARY DISORDERS GALDERMA RESEARCH & DEVELOPMENT (FR) 2006-10-05 WO disclosed